SCHEMBL5594524

SCHEMBL5594524

CCCCOC(=O)N1CCN(C)CC1

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.65
SMN1; SMN2 Q16637 2/20 0.65
LMNA P02545 1/20 0.65
HRH2 P25021 8/20 0.50
HRH1 P35367 8/20 0.50
ALDH1A1 P00352 4/20 0.45
HTT P42858 1/20 0.44
KDM4E B2RXH2 2/20 0.44
NPC1 O15118 1/20 0.44
HTR1A P08908 1/20 0.43
ATM Q13315 1/20 0.42
GAA P10253 1/20 0.42
RECQL P46063 1/20 0.42
TDP1 Q9NUW8 2/20 0.42
CYP1A2 P05177 1/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21428430 0.95 POLB (0.58) POLBSMN1; SMN2LMNAHRH2HRH1
SCHEMBL22018193 0.93 POLB (0.57) POLBSMN1; SMN2LMNAHRH2HRH1
SCHEMBL20943327 0.93 POLB (0.57) POLBSMN1; SMN2LMNAHRH2HRH1
SCHEMBL9405372 0.92 POLB (0.73) POLBSMN1; SMN2LMNAHRH2HRH1
SCHEMBL7034033 0.89 SMN1; SMN2 (0.50) POLBSMN1; SMN2LMNAALDH1A1HTT
SCHEMBL5594520 0.85 POLB (0.65) POLBSMN1; SMN2LMNAHRH2HRH1
SCHEMBL14590615 0.85 POLB (0.65) POLBSMN1; SMN2LMNAHRH2HRH1
SCHEMBL27826063 0.85 SMN1; SMN2 (0.65) POLBSMN1; SMN2LMNAHRH2HRH1
SCHEMBL3634052 0.85 SMN1; SMN2 (0.69) POLBSMN1; SMN2LMNAHRH2HRH1
SCHEMBL1859157 0.85 SMN1; SMN2 (0.69) POLBSMN1; SMN2LMNAHRH2HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1189606-B1 NOVEL IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING IRON CHELATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS YEDA RES & DEV (IL) 2007-08-15 EP claimed
US-6855711-B1 Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2005-02-15 US claimed
EP-3518334-B1 NON-AQUEOUS ELECTROLYTE SOLUTION ADDITIVE, NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING SAID ADDITIVE LG CHEMICAL LTD (KR) 2021-04-21 EP disclosed
EP-3778571-A1 (2E,4E)-5-PHENYL-PENTA-2,4-DIEN-1-ONE DERIVATIVE Bioway, Inc. (KR) 2021-02-17 EP disclosed
EP-3322706-B1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2020-11-11 EP disclosed
US-20200157048-A1 (2E,4E)-5-PHENYL-PENTA-2,4-DIEN-1-ONE DERIVATIVE BIOWAY., INC (KR) 2020-05-21 US disclosed
WO-2019190177-A1 (2E,4E)-5-PHENYL-PENTA-2,4-DIEN-1-ONE DERIVATIVE 주식회사 바이오웨이 2019-10-03 WO disclosed
US-20170267685-A1 HETEROARYL COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2017-09-21 US disclosed
US-9695132-B2 Heteroaryl compounds and uses thereof CELGENE CAR LLC (BM) 2017-07-04 US disclosed
US-9663524-B2 Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors CELGENE CAR LLC (BM) 2017-05-30 US disclosed
US-20160009733-A1 REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT UNIVERSITY OF WOLLONGONG (AU) 2016-01-14 US disclosed
US-7960413-B2 Pyrazole compounds MERCK PATENT GMBH (DE) 2011-06-14 US disclosed
US-20110008285-A1 NOVEL CYCLOSPORIN ANALOGUES ENANTA PHARMACEUTICALS, INC. 2011-01-13 US disclosed
US-7842695-B2 Substituted pyrazole compounds MERCK PATENT GMBH (DE) 2010-11-30 US disclosed
US-7566709-B2 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2009-07-28 US disclosed
US-20080214572-A1 Selected Tetracyclic Tetrahydrofuran Derivatives Containing a Cyclic Amine Side Chain FERNANDEZ-GADEA FRANCISCO JAVIER 2008-09-04 US disclosed
EP-1189606-B1 NOVEL IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING IRON CHELATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS YEDA RES & DEV (IL) 2007-08-15 EP disclosed
US-6855711-B1 Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2005-02-15 US disclosed
CN-1136191-C Carboxy substituted carboxamide derivatives as tachykinin receptor antagonists ������ҩ�����޹�˾ 2004-01-28 CN disclosed
CN-1301253-A Carboxy substituted carboxamide derivatives as tachykinin receptor antagonists AVENTIS PHARMACEUTICAL INC (US) 2001-06-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200157048-A1 (2E,4E)-5-PHENYL-PENTA-2,4-DIEN-1-ONE DERIVATIVE PCK1, PCK2, ACACB POLB 2434/4885SMN1; SMN2 4751/4885LMNA 1567/4885
US-20170267685-A1 HETEROARYL COMPOUNDS AND USES THEREOF PRKACA, PRKDC, AURKC POLB 2389/4885SMN1; SMN2 4743/4885LMNA 3640/4885
US-20080214572-A1 Selected Tetracyclic Tetrahydrofuran Derivatives Containing a Cyclic Amine Side Chain HTR2C, HTR2A, HTR5A POLB 2932/4885SMN1; SMN2 2040/4885LMNA 4371/4885
US-20160009733-A1 REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT NOS1, NOS2, NOS3 POLB 3945/4885SMN1; SMN2 4885/4885LMNA 4677/4885
US-20110008285-A1 NOVEL CYCLOSPORIN ANALOGUES HAVCR2, CHP1, TSLP POLB 4466/4885SMN1; SMN2 3645/4885LMNA 4748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.